The FDA has approved a new inhaler called Breztri Aerosphere for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This medicine combines three different drugs in one inhaler: a corticosteroid to reduce inflammation, an anticholinergic to relax airways, and a long-acting beta2-agonist (LABA) to help keep airways open. It is meant for people with moderate to very severe COPD who need daily treatment to prevent flare-ups.
Breztri Aerosphere is not for sudden breathing problems or for asthma. It should be used exactly as prescribed, typically two puffs twice a day. The approval was based on studies showing that it reduced the number of moderate or severe COPD flare-ups compared to other combinations.
This approval offers a new option for people with COPD. However, it is important to remember that this medicine is not a rescue inhaler. Patients should continue to use their rescue inhaler for sudden symptoms. Also, after using Breztri Aerosphere, you should rinse your mouth with water to help prevent thrush (a mouth infection).
If you have COPD, talk to your doctor about whether Breztri Aerosphere might be right for you. Your doctor can help you understand the benefits and risks based on your specific health needs.